Revenue Showdown: Celldex Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.

Biotech Revenue Battle: BioCryst vs. Celldex

__timestampBioCryst Pharmaceuticals, Inc.Celldex Therapeutics, Inc.
Wednesday, January 1, 2014136080003586000
Thursday, January 1, 2015482570005480000
Friday, January 1, 2016263530006786000
Sunday, January 1, 20172518600012743000
Monday, January 1, 2018206530009538000
Tuesday, January 1, 2019488350003573000
Wednesday, January 1, 2020178120007418000
Friday, January 1, 20211571700004651000
Saturday, January 1, 20222708270002357000
Sunday, January 1, 20233314120006883000
Loading chart...

Unleashing insights

Revenue Showdown: A Tale of Two Biotechs

In the competitive world of biotechnology, revenue growth is a key indicator of success. Over the past decade, BioCryst Pharmaceuticals, Inc. has consistently outperformed Celldex Therapeutics, Inc. in terms of revenue. Starting in 2014, BioCryst's revenue was nearly four times that of Celldex, and by 2023, it had surged to over 48 times more. This remarkable growth trajectory highlights BioCryst's strategic advancements and market positioning.

A Decade of Growth

From 2014 to 2023, BioCryst's revenue increased by an impressive 2,300%, while Celldex saw a modest growth of around 92%. The year 2021 marked a significant leap for BioCryst, with revenues skyrocketing by 870% compared to 2020. In contrast, Celldex's revenue peaked in 2017 but has since experienced fluctuations. This data underscores the dynamic nature of the biotech industry and the importance of innovation and market adaptation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025